Key result
DHPLC identifies FBN1 mutations in 76% of previously unscreened definitive Marfan syndrome cases.
Why the study?
Mutation detection in the large FBN1 gene causing Marfan syndrome is technically challenging, necessitating development of an efficient screening method.
Does denaturing high-performance liquid chromatography (DHPLC) efficiently detect FBN1 mutations in individuals with Marfan syndrome and related disorders?
Observational (n=94)
Does denaturing high-performance liquid chromatography (DHPLC) efficiently detect FBN1 mutations in individuals with Marfan syndrome and related disorders?
DHPLC is a highly efficient method for detecting FBN1 mutations in patients with Marfan syndrome, improving detection rates even in samples previously screened by other methods.
Answers are grounded in this paper and cite their sources.
DHPLC may aid FBN1 screening in Marfan syndrome; leaves open its place versus sequencing in clinical diagnostics.
Marfan syndrome (MFS), a common connective tissue disorder, is caused by fibrillin-1 (FBN1) mutations that are scattered throughout the gene and are largely unique to individual families. Mutation detection in this large gene of 65 exons is a considerable technical challenge. To develop an efficient method capable of identifying all possible mutations in this gene, we have explored the use of a novel denaturing high-performance liquid chromatography (DHPLC) system. This technique compares two or more chromosomes as a mixture of denatured and reannealed PCR amplicons. Under partially denaturing conditions, heteroduplexes can be separated from homoduplexes. A panel of 94 DNA samples from individuals with MFS or related connective tissue disorders was screened exon-by-exon by this method. A total of 66 unique heteroduplex profiles was identified. Sequencing of the amplicons detected 37 novel and two previously reported mutations, as well as 15 novel and 10 known polymorphisms or unique sequence variants that are probably of no clinical significance. Of the 34 mutations found in definitive MFS cases, 16 were identified in the 21 samples that had not been screened before (76% detection rate) and 17/40 (43%) were in samples previously screened by other mutation detection methods. In 32 individuals with MFS-related phenotypes, five FBN1 mutations were identified (16%). Our results demonstrate the power of the DHPLC method to detect FBN1 mutations. It should be applicable for mutation screening in any gene in a large population.
No takes yet. Share an insight, caveat, or question.
Oefner et al. (1997) conducted an observational in Marfan syndrome and related connective tissue disorders (n=94). Denaturing high-performance liquid chromatography (DHPLC) was evaluated on FBN1 mutation detection rate in previously unscreened definitive MFS cases. Denaturing high-performance liquid chromatography (DHPLC) effectively detected FBN1 mutations, achieving a 76% detection rate in previously unscreened definitive Marfan syndrome cases.
Synapse has enriched 10 related papers. Consider them for comparative context: